Pfizer: positive results for a growth hormone
(CercleFinance.com) - Pfizer and Opko have announced positive results for a Phase III study for Somatrogon, a long-acting human growth hormone to treat children with growth hormone deficiency.
The study showed non-inferiority of this candidate drug in a weekly dose in pre-pubertal children, compared with somatropin in a daily dose, in terms of the growth rate after 12 months of treatment, thus reaching its primary endpoint.
For the record, both groups concluded a somatrogon agreement in 2014, under which Opko is responsible for conducting the clinical program and Pfizer, the drug's registering and marketing.
Copyright (c) 2019 CercleFinance.com. All rights reserved.
The study showed non-inferiority of this candidate drug in a weekly dose in pre-pubertal children, compared with somatropin in a daily dose, in terms of the growth rate after 12 months of treatment, thus reaching its primary endpoint.
For the record, both groups concluded a somatrogon agreement in 2014, under which Opko is responsible for conducting the clinical program and Pfizer, the drug's registering and marketing.
Copyright (c) 2019 CercleFinance.com. All rights reserved.